J. Randall Curtis, MD, MPH is Chair in Pulmonary and Critical Care Medicine, Department of Medicine | UW Medicine; past-president of the American Thoracic Society
He says with regard to Remdesivir:
“I think the data suggests that there is probably some benefit in terms of shortening the course of illness and maybe preventing deterioration. If there is any benefit in terms of survival, that seems likely to be too small a benefit to be detected in the existing studies.”
Gabriel Lockhart, MD, is a pulmonologist in the division of pulmonary, critical care and sleep medicine at National Jewish Health in Colorado.
While he questions whether Remdesivir is “truly efficacious” in patients with COVID-19, the drug “has been incorporated into my ICU practice… utilizing it in all patients that don’t have a contraindication.”
